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Abstract Chronic Myeloid Leukaemia (CML) is charac-
terized by expression of the constitutively active Bcr-Abl
tyrosine kinase. We have shown previously that the
negative growth regulator, CCN3, is down-regulated as a
result of Bcr-Abl kinase activity and that CCN3 has a
reciprocal relationship of expression with BCR-ABL. We
now show that CCN3 confers growth regulation in CML
cells by causing growth inhibition and regaining sensitivity
to the induction of apoptosis. The mode of CCN3 induced
growth regulation was investigated in K562 CML cells
using gene transfection and treatment with recombinant
CCN3. Both strategies showed CCN3 regulated CML cell
growth by reducing colony formation capacity, increasing
apoptosis and reducing ERK phosphorylation. K562 cells
stably transfected to express CCN3 showed enhanced
apoptosis in response to treatment with the tyrosine kinase
inhibitor, imatinib. Whilst CCN3 expression was low or
undetectable in CML stem cells, primary CD34+ CML
progenitors were responsive to treatment with recombinant
CCN3. This study shows that CCN3 is an important growth
regulator in haematopoiesis, abrogation of CCN3 expres-
sion enhances BCR-ABL dependent leukaemogenesis.
CCN3 restores growth regulation, regains sensitivity to
the induction of apoptosis and enhances imatinib cell kill in
CML cells. CCN3 may provide an additional therapeutic
strategy in the management of CML.
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Introduction
Chronic Myeloid Leukaemia (CML), a haematopoietic stem
cell disorder, is characterised by the expression of the
chimaeric bcr-abl fusion gene (or Philadelphia chromo-
some, Ph+) formed from a reciprocal translocation between
the bcr and abl genes on chromosomes 9 and 22 (Nowell
and Hungerford 1960; Rowley 1973). The fusion gene
encodes a constitutively active Bcr-Abl protein tyrosine
kinase and expression culminates in alterations of cell pro-
liferation, differentiation and resistance to the induction of
apoptosis (Deininger et al. 2000; Jorgensen and Holyoake
2001). Expansion of the leukaemic clone presents as an
accumulation of immature haematopoietic progenitor cells
in the bone marrow (BM) and raised levels of myeloid cells
in the peripheral blood (PB) (Clarkson et al. 1997; Wong
and Witte 2001). CML is regarded as a triphasic disease; an
indolent chronic phase of variable duration precedes
progression to an accelerated phase leading on to the more
severe blast crisis. The development of tyrosine kinase
inhibitors (TKIs) has revolutionised the treatment of CML.
Imatinib (Glivec, Gleevec), is now the gold standard and
first line treatment for CML (Deininger and Holyoake
2005). Imatinib has been effective in inducing haemato-
poietic response in most cases and complete cytogenetic
responses have been observed for 80-95% patients with
chronic phase disease and 25-37% patients with advanced
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Clark, NJ 07066, USAdisease (accelerated and blast crisis) (Kumar 2006). Imatinib
and its derivatives suppress but do not fully eradicate the
leukaemic clone (Deininger and Holyoake 2005) and a
proportion of patients remain unresponsive. An increasing
number of patients are developing resistance to TKIs and it
is clear that new treatment strategies are required.
We have previously identified down regulation of the
negative growth regulator, CCN3, using DNA microarray
analysis for a murine stem cell CML model to identify
altered gene expression caused by the initial effects of Bcr-
Abl kinase activity (McCallum et al. 2006). CCN3 is a
member of the CCN family of growth regulatory proteins
and roles for the CCN proteins are clearly established in
fundamental biological processes such as cell proliferation,
attachment, migration, differentiation, wound healing,
angiogenesis and tumorigenesis (Perbal 2001). CCN pro-
teins are multi-modular mosaic proteins containing four
conserved modules which are present in other unrelated
extracellular proteins. CCN3 comprises five distinct struc-
tural domains, a secretory peptide (SP) followed by the 4
conserved modules; insulin–like growth factor binding
protein (IGFBP), Von Willebrand type C repeat (VWC),
thrombospondin type I domain (TSP-1) and a cysteine knot
carboxyl terminal (CT). CCN3 is mostly associated with
exerting negative growth regulation. CCN3 was first
isolated in a nephroblastoma model of Wilms’s tumour
where expression was associated with a differentiated
phenotype and anti-proliferative activity (Chevalier et al.
1998). Although CCN3 was able to reduce the growth rate
of Ewings sarcoma transfectants ex vivo (Scotlandi et al.
2003), CCN3 expression was associated with poor progno-
sis and shown to increase cell motility resulting in enhanced
metastatic potential (Benini et al. 2005; Manara et al.
2002). Increased levels of CCN3 expression have been
correlated with reduced tumorigenicity and low metastatic
potential in glioblastomas (Li et al. 1996) and an inverse
relationship between CCN3 expression and tumour grade
has been established for neuroblastoma and echondroma
(Perbal 2001). CCN3 expression in conjunction with
connexin-43 impaired human choriocarcinoma cell ability
to induce tumour growth in vitro (Gellhaus et al. 2003).
CCN3 is most commonly associated with negative growth
regulation; reduced proliferation, cell differentiation and
involvement in cell adhesion (Planque and Perbal 2003).
We have previously shown that CCN3 expression is low
or absent in CML bone marrow (BM) mononuclear cells
and expression increases to levels comparable with normal
bone marrow (NBM) upon treatment with Imatinib
(McCallum et al. 2006). This finding was also specific to
the CD34+ progenitor cell population responsible for clonal
expansion. In this study, we have used the human CML cell
line (K562) to further investigate the mode of CCN3
induced growth regulation. We have evaluated the use of
recombinant CCN3 (rCcn3) as an agent, alone and in
combination with imatinib and then assessed primary
human CML stem cell response to rCcn3.
Materials and methods
Cell lines
K562 cells were obtained from Deutsche Sammlung von
Mikrorganismen und Zellkulturen (DSMZ, GmbH,
Braunschweig, Germany) and HL-60 cells were obtained
from the European Collection of Cell Cultures (ECACC,
Salisbury, UK). All cell lines were maintained in RPMI-
1640 medium supplemented with 10% fetal calf serum
(Gibco BRL, Paisley, UK) cultured at 37°C in a humidified
atmosphere (5% CO2 in air). Cells were subcultured twice
weekly to maintain a log phase culture.
Primary CML samples and normal controls
Bone marrow aspirate samples and peripheral blood were
obtained with informed consent from normal bone marrow
donors and CML patients at diagnosis. All human samples
were obtained with ethical approval from the local ethics
review committee and those involved gave their informed
consent for participation in accordance with the Declaration
of Helsinki. Samples were collected in RPMI-1640 supple-
mented with 10% fetal calf serum and containing 100 IU
preservative free heparin (Leo Laboratories Ltd, Princes
Risborough, UK). Mononuclear and neutrophil cells were
separated over Ficoll-Hypaque (Pharmacia Biotech,
Uppsala, Sweden) using standard procedures (English and
Andersen 1974). CD34 positive cells were prepared using
the MACS Direct CD34 Progenitor Cell Isolation kit
(Miltenyi Biotech Ltd, Bisley, UK).
CCN3 transfection of K562 cells
K562 cells were nucleofected following the manufacturer’s
instructions using the Cell Line Nucleofector kit V, program
T-16 (Amaxa, GmbH, Cologne, Germany) and transfected
with 5 μg of either vector (pCb6+; Invitrogen) or vector
containing CCN3 sequence. Transfection was performed in
triplicate and the functional consequences of CCN3
expression were evaluated 24 hours after transfection (mean
transfected cells, 97.9%±0.4%). Protein was extracted and
Western blotting performed to confirm CCN3 expression.
To obtain cells stably expressing CCN3, K562 cells were
nucleofected (as above) and stable transfectants were selected
in G418 (Invitrogen) at a concentration of 800µg/ml.
Cells transfected with the empty vector pCB6+ were used as
ac o n t r o l .
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K562 cells (1x10
6) were treated with recombinant CCN3
(rCcn3; Peprotech EC, London, U.K.) in vitro and cultured
at 37°C in a humidified atmosphere (5% CO2 in air) for 24
and 48 h. After 24 h, cells were transferred to methyl
cellulose culture (see below) and protein lysates were
prepared (as described in Western Blotting). After 48 h,
cells were fixed and prepared for flow cytometric analysis
(as described in Flow cytometry). K562 cells (1×10
6) were
treated with imatinib (1µM and 5µM) for 96 h. Cells were
fixed and prepared for flow cytometric analysis (as
described in Flow cytometry).
Evaluation of clonogenic capacity
Cells (1×10
4) were plated in triplicate in methyl cellulose
(Miltenyi Biotech, U.K.) and incubated at 37°C in a
humidified atmosphere (5% CO2 in air) for 7 days.
Colonies were counted using an inverted microscope
(Olympus model 214034; Olympus, Tokyo, Japan; magni-
fication×40).
Western blot analysis
Protein was extracted from cells by suspending in RIPA
buffer (1× PBS, 1% Nonidet NP-40, 0.1% SDS) containing a
cocktail of protease inhibitors (Complete Mini Cocktail,
Roche Diagnostics Ltd, Lewes, UK) at a concentration of
10
7 cells / ml and lysing for 10 minutes on ice. Samples were
sonicated for 10 seconds to ensure complete lysis, centri-
fuged at 10,000 g at 4°C for 10 min and the supernatant
removed for analysis. Total protein content was determined
by the Bradford protein method using the BCA protein assay
kit (Pierce, Cramlington, UK). Protein (15 μg) was loaded
onto a pre-cast Bis-Tris polyacrylamide gel (10%) using the
Novex mini gel system (Invitrogen, Paisley, UK) and
subsequently transferred to a PVDF membrane. CCN3
expression was detected using an antibody raised against
the C terminal of CCN3
22. Immunoblots were visualised by
enhanced chemiluminescence (Supersignal West Pico and
Supersignal West Dura substrates, Pierce).
Antibodies used in study
The K19M and NH5 antibodies were raised against the
carboxyl terminal of CCN3 and were kindly provided by B.
Perbal. Both antibodies were diluted 1/1,000 in Western
Breeze Blocker Diluent (Invitrogen, Paisley, U.K.) and used
in the Western blotting procedure. Total ERK1/2 and
phosphorylated ERK1/2 were detected using the p44/42
MAP kinase antibody (1/1,000, Cat#9102; Cell Signaling
Technology, Boston, MA, USA) and Phospho p44/42 MAP
kinase antibody (1/2,000, Cat#9106; Cell Signaling Tech-
nology, USA) respectively. Anti-cleaved Caspase-3
antibody (Cat#96648; Cell Signaling Technology, USA)
was used at a dilution of 1/1,000. Equivalent protein
loading was controlled by monitoring actin expression




5) were fixed in 70% ethanol for flow
cytometric analysis of cell cycle status. Fixed cells were
resuspended in PBS and incubated in RNase A (100 mg/
mL, Qiagen) and propidium iodide (40 mg/mL, Calbio-
chem) for 30 minutes at 37°C. Samples were analyzed on a
Coulter Epics Elite Cell Sorter (Beckman Coulter, High
Wycombe, United Kingdom). Data were collected on the
basis of peak signal versus integral signal to exclude
doublets. Analysis was performed on 20,000 events using
winMDI software (http://facs.scripps.edu/software.html)
and data were generated and then ranked from a common
gate in the subG0 area.
Real-time PCR analysis of BCR-ABL and CCN3
expression
RQ-PCR was performed with an ABI PRISM 7500
Sequence Detector which exploits TaqMan probe based
chemistry (Applied Biosystems, Foster City, CA). The 5′
reporter used was 6-carboxyfluorescein (FAM) and the 3’
quencher was 6-carboxy-tetramethylrhodamine (TAMRA).
Primers and probes for CCN3 were designed against
GenBank published sequences in association with Primer
Express (Applied Biosystems). Primer and probe sets for
BCR-ABL were used as recommended by the Europe
Against Cancer protocol (Beillard et al. 2003; Gabert et
al. 2003). The amplification reactions (12.5 μL) contained
59 ng cDNA equivalents (or control), 1×Taqman universal
PCR master mix, final concentrations of 5 mM MgCl2,
0.2 mM deoxyadenosine deoxycytosine deoxyguanosine
triphosphate (dATP/ dCTP/ dGTP), 0.4 deoxyuridine
triphosphate ( dUTP), 0.125 U AmpliTaq Gold, 2 μM
primers (forward and reverse) and 200 nM TaqMan probe.
Amplifications were performed following an initial
2-minute incubation at 50°C to allow uracil-N-glycosylase
(UNG) to destroy any contaminating RNA, followed by
treatment at 95°C for 10 min to inactivate the UNG enzyme
and activate the AmpliTaq Gold DNA polymerase. This
was followed by 40 to 45 cycles of denaturing at 95°C for
15 s and annealing/extension at 60°C for 1 min. Data were
collected and analysed with Sequence Detector v1.6.3
software (Applied Biosystems) as previously described
(McCallum et al. 2006) to generate gene copy number.
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CCN3 reduces cell growth and causes induction
of apoptosis in K562 cells
To investigate the functional capacity of CCN3, we used
both (i) transfection and (ii) recombinant protein to
determine effect. Cell growth was measured using colony
formation in methyl cellulose culture and was further
evaluated using cell cycle analysis and Western blotting to
detect the intracellular signaling events of caspase 3
cleavage and ERK phosphorylation.
CCN3 expression exerts growth regulation in K562 cells
CCN3 was transfected into K562 cells using nucleofec-
tor™ technology and compared to cells transfected with
empty vector (EV) and cells treated with imatinib (1µM).
Increased Ccn3 expression significantly reduced K562 cell
colony formation capacity by 65.4%±18.8 to that of
control (n=3, p=0.027)(Fig. 1a). In addition, increased
levels of Ccn3 caused cells to accumulate in the subG0
region of cell cycle (Mean subG0 9.9%±4.6 for Control
and 21.8%±0.7 for Ccn3 expressing cells (n=3, p=0.027)
(Fig. 1b). Western blot analysis showed that Ccn3
expression was undetected in K562 cells (EV) whilst
transfection with vector containing CCN3 dramatically
increased expression levels (Fig. 1c). Increased expression
was accompanied by an increase in the levels of cleaved
caspase 3 product and a reduction in phosphorylation of
Erk2 (Mean reduction 42%±10.4, n=3 p=0.01) (Fig. 1c).
Optical densitometry was performed to show changes in
the magnitude of Erk phosphorylation and cleaved caspase
3( F i g .1d).
Fig. 1 CML cells expressing CCN3 exhibit growth regulation. K562
cells transfected with CCN3 (CCN3) were compared to cells
transfected with empty vector (EV) and cells treated with imatinib
(1µM). Colony formation was measured after 7 days and is shown as
a percentage of colony formation for cells transfected with empty
vector (a). Induction of apoptosis was measured by the number of
events within the sub G0 region of cell cycle; analysis was performed
on 20,000 events using winMDI software and data were generated and
then ranked from a common gate in the subG0 area (b). Western blot
analysis was performed to identify Ccn3 expression, accumulation of
cleaved caspase 3 and levels of phosphorylated Erk1 and Erk2 (c).
Actin expression is shown as a control for protein loading. Optical
densitometry was performed to show changes in Erk phosphorylation
and cleaved caspase 3 (d)
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CCN3
K562 cells were treated with recombinant Ccn3 (rCcn3,
1nM) and compared to untreated cells (Control). Cells
treated with rCcn3 had reduced colony formation
capacity 14%±2.1 compared to untreated cells (Fig. 2a)
(n=3, p=0.015). Similarly, rCcn3 caused an accumulation
of cells within the subG0 area of cell cycle (Mean for
subG0 9.3%±3.9 and 23.7%±6.9 for control and rCcn3
respectively (Fig. 2b) (n=3, p=0.014). Western blot
analysis showed reduced Erk phosphorylation and an
increase in cleaved caspase 3 levels as a consequence of
rCcn3 treatment (Fig. 2c) (n=3). Optical densitometry was
performed to show alterations in levels of Erk phosphor-
ylation and cleaved caspase 3 as a result of rCCN3
treatment (Fig. 2d).
CCN3 expression enhances Imatinib induced apoptosis
Since CCN3 expression and treatment with recombinant
Ccn3 restored growth regulation and induction of apoptosis
in CML cells, we wished to investigate if CCN3 could
augment imatinib induced cell death. K562 cells were
transfected with vector or vector containing CCN3. Clones
stably expressing vector constructs were selected using
G418 resistance. Ccn3 expressing cells had a reduced
growth rate compared to mock transfected cells (49%
reduction in growth by day 5, data not shown; (p=
0.005)). Cells expressing CCN3 (CCN3) or empty vector
(Mock) were then untreated (control) or treated with
Imatinib (1 μMo r5μM) for 48 h. CCN3 expression
increased the number of events within the subG0 phase of
cell cycle for both treatment with 1 μM imatinib (24.5%±
4.6 subG0 events for CCN3 and 10.8%±4.1 for mock
Fig. 2 CML cells respond to treatment with recombinant Ccn3. K562
cells treated with recombinant Ccn3 (rCcn3, 1nM) were compared to
untreated cells (Control) and evaluated for growth regulation. Colony
formation was measured after 7 days and is shown as a percentage of
colony formation by control cells (a). Induction of apoptosis was
measured by the number of events within the sub G0 region of cell
cycle; analysis was performed on 20,000 events using winMDI
software and data were generated and then ranked from a common
gate in the subG0 area (b). Western blot analysis was performed to
identify accumulation of cleaved caspase 3 and levels of phosphor-
ylated Erk1 and Erk2 (c). Actin expression is shown as a control for
protein loading. Optical densitometry is shown for changes in Erk
phosporylation and levels of cleaved caspase 3 for rCCN3 treated cells
in comparison to control (d)
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imatinib (32.3%±3.3 subG0 events for CCN3 and 16.1%±
2.8 for mock transfected cells respectively (n=3, p=0.001))
at 48 h (Fig. 3a). To further evaluate the magnitude and
longevity of CCN3 enhanced apoptosis, CCN3 and mock
transfected cells were treated with Imatinib (5 μM) for
96 h. At 48 h, CCN3 expressing cells showed enhanced
apoptosis in response to imatinib when compared to mock
transfected cells (45.0%±6.7 and 28.2%±2.8 of events in
sub G0 for CCN3 and mock transfected cells respectively
(n=3, p=0.030 (Fig. 3b). CCN3 expressing cells showed
enhanced susceptibility to imatinib induced apoptosis at
72 h and 96 h; (66.7%±0.6 and 44.2%±1.8 of events in sub
G0 for CCN3 and mock transfected cells respectively at
72 h (n=3, p=0.001)) and (75.1%±3.9 and 52.7%±1.9 of
events in sub G0 for CCN3 and mock transfected cells
respectively at 96 h (n=3, p=0.002)).
CCN3 expression is altered in CML
We have previously shown that CCN3 expression is down-
regulated as a consequence of Bcr-Abl kinase activity in
Fig. 3 CCN3 expression enhances Imatinib induced apoptosis. K562
CML cells were stably transfected with CCN3 (CCN3) or vector alone
(Mock) and treated with Imatinib (1µM or 5µM) for 48 h. Flow
cytometric analysis was performed on 20,000 events, data were then
generated and ranked from a common gate in the subG0 area. The
number of events in the subG0 area for CCN3 and mock transfected
cells are shown (a). CCN3 and mock transfected cells were treated
with 5µM imatinib for a period of 96 h and flow cytometric analysis
was performed (as above). The number of events in the subG0 area for
CCN3 and mock transfected cells are shown (b)
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expression was performed on BM and peripheral blood
(PB) mononuclear cell extracts from CML patients at
diagnosis. BCR-ABL expression was generally high (3.28±
4.9×10
4 copies per 5µl cDNA for BM and 1.34±1.1×10
4
copies per 5µl cDNA for PB) whilst CCN3 expression was
low (6.13±5.6×10
2 copies per 5µl cDNA for BM and 2.58±
3.7×10
3 copies per 5µl cDNA for PB) (Fig. 4a). Analysis of
individual patients following treatment with imatinib showed
a clear trend; those with low or undetectable levels of CCN3
at diagnosis were more likely to achieve a 3 log reduction
within 6 months (optimal response), whilst those with higher
levels of expression had a sub-optimal response to imatinib
treatment (data not shown). To further investigate this
phenomenon, protein was prepared from CD34+, mononu-
clear and neutrophil cells derived from NBM and from CML
BM where the patient had a sub-optimal response to
imatinib. Western blot analysis showed that CCN3 expres-
sion was high in normal CD34+ stem and mononuclear cells
whilst CCN3 expression was undetectable in CML CD34+
stem cells and neutrophils (Fig. 4b). To then determine if
primary human CML stem cells were responsive to Ccn3,
we treated CML CD34+ stem cells from peripheral blood
samples at diagnosis with recombinant Ccn3 (rCcn3; 1nM-
1pM) for 24 h. Cells were then plated in methyl cellulose
and counted after seven days. Treatment with imatinib
(1 μM) reduced the clonogenic capacity of CML CD34+
cells by 33.1%±11.4 (n=3, p=0.007) whilst treatment with
rCcn3 showed dose dependent growth inhibition; 19.5%±4.0
for 1nM (n=3, p=0.001), 17.8%±2.7 for 100pM (n=3, p<
0.001) and 16.6%±4.6 for 10pM rCcn3. Treatment with
1pM rCcn3 did not significantly affect colony formation
capacity (Fig. 4c).
Discussion
CCN3, a member of the CCN family of growth regulatory
proteins has been shown to exert growth enhancing and
growth inhibitory properties in a cell context specific
manner. CCN3 is associated with increased invasive
potential and metastasis in Ewings sarcoma (Benini et al.
2005; Manara et al. 2002) and is linked with expression of
the multi drug resistant proteins in osteosarcoma (Perbal et
Fig. 3 (continued)
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transformation and early detection of malignancy (Maillard
et al. 2001). In contrast, CCN3 acts as a tumour suppressor
in melanoma, glioblastoma, adrenocortical tumours and in
CML (McCallum and Irvine 2009). Reduced CCN3
expression is associated with the disorganized structure
and increased proliferative capacity in the epidermis in
melanoma and increased aggressiveness in glioblastomas
(Fu et al. 2004; Fukunaga-Kalabis et al. 2007; Sin et al.
2007). CCN3 secretion is a recognised mechanism used in
metastatic adrenocortical tumours and in CML cells to
evade growth regulation. In CML, reduced expression of
CCN3 is a direct consequence of Bcr-Abl kinase activity
and cellular Ccn3 is rapidly exported to evade growth
inhibition. In this report we have investigated CCN3 mode
of regulation in CML cells.
Fig. 4 Primary CML cells express low levels of CCN3 and respond
to recombinant Ccn3. CCN3 and BCR-ABL levels at diagnosis were
evaluated using Real-time PCR (EAC protocol for BCR-ABL
expression). Gene copy number for CCN3 and BCR-ABL expression
levels were compared for BM (n=16) and PB (n=9) samples (a).
Western blot analysis was performed to detect Ccn3 expression levels
in extracts from CD34+(1), mononuclear (2) and neutrophil (3) cell
preparations derived from NBM and CML BM at diagnosis. Ccn3 was
detected using the NH5 antibody and expression is shown compared
with levels of actin (b). Primary CML CD34+ cells (n=3) were
isolated from CML peripheral blood (PB) at diagnosis. Cells were
treated with rCcn3 (1nM – 1pM) or untreated (Control) for 24 h prior
to plating in methyl cellulose. Colonies were counted after 7 days and
are expressed as a percentage of colony formation compared to control
(c *denotes p<0.05)
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expression of CCN3 or treatment with the recombinant
protein results in a significant reduction in cell growth. The
discrepancy between CCN3 expression and treatment with
rCCN3 may be due to sustained CCN3 expression over the
experimental period for colony formation (7 days) as
opposed to a 24 h pre-treatment prior to plating in methyl
cellulose culture. CCN3 reduced phosphorylation of Erk
and increased apoptosis by enhancing caspase 3 cleavage.
We have previously shown that reduced Erk phosphoryla-
tion as a consequence of the U0126 inhibitor, correlates
with reduced clonogenic and proliferative capacity of K562
cells. CCN3 may compromise cell survival by reducing Erk
phosphorylation causing decreased expression of pro-
survival factors such as BCL-2, BCL-xL and MCL-1
(Balmanno and Cook 2009). CCN3 expression was shown
to augment imatinib induced apoptosis and suggests CCN3
acts a tumour suppressor or pro-apoptotic factor.
We have previously shown CML patients at diagnosis
have low or undetectable levels of CCN3 and CML CD34+
stem cells have low CCN3 expression which increases in
response to imatinib treatment (McCallum et al. 2006).
Ongoing monitoring of CML patients has subsequently
demonstrated that a sub-population of patients have higher
levels of CCN3 at diagnosis. These patients did not achieve
a 3 log reduction in BCR-ABL levels within 6 months
which is known to be associated with poorer prognosis.
Analysis of Ccn3 protein within these samples showed that
although mononuclear cells expressed Ccn3, the stem cell
population had low or undetectable levels of Ccn3
expression. Since Ccn3 is clearly expressed in stem,
mononuclear and neutrophil cells in NBM, CCN3 down-
regulation is a key event in BCR-ABL leukaemogenesis.
CCN3 appears to compromise BCR-ABL+ cell resistance
to the induction of apoptosis. Primary CML CD34+ stem
cells were responsive to recombinant Ccn3 which demon-
strates a novel avenue for further evaluation in the
management of CML.
CCN3 is a key regulator of haematopoiesis; de-regulation
within this pathway enhances BCR-ABL leukaemogenesis
by promoting cell survival and eliminating pro-apoptotic
factors through the Erk signalling pathway. Manipulation of
Ccn3, provides a novel strategy for therapeutic intervention
to overcome oncogene mediated survival signals and restore
apoptosis.
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